For this reason, it has been suggested that immunotherapy could improve response provided that expression of TGF-β concentrations at the tumour site can be decreased; one approach to reducing TGF-β expression is through c-Met blockage, which lowers the production of TGF-β, thus sensitizing tumour cells to immune mechanisms. Here, TGFB1 is linked to neoplasm.